How have HLOSF shares performed in 2024?

Healios K.K.'s stock was trading at 1.59 at the beginning of the year. Since then, HLOSF stock has decreased by 37.4% and is now trading at 0.99. View the best growth stocks for 2024 here .

Are investors shorting Healios K.K.?

Healios K.K. saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 365,900 shares, a drop of 6.4% from the March 31st total of 391,100 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days. View Healios K.K.'s Short Interest .

How do I buy shares of Healios K.K.?

Shares of HLOSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:HLOSF

Healios K.K. (HLOSF) Stock Price, News & Analysis

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Free HLOSF Stock Alerts

0.99

+0.05 (+5.64%)

(As of 04/25/2024 09:04 PM ET)

Compare

Today's Range: 0.99
▼
0.99
50-Day Range: 0.94
▼
0.99
52-Week Range: 0.94
▼
1.31

Volume: 200 shs
Average Volume: 1,260 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Short Interest

Get Healios K.K. alerts:

Ad Weiss Ratings

Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

About Healios K.K. Stock (OTCMKTS:HLOSF)

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.

HLOSF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HLOSF Stock News Headlines

April 26, 2024 | americanbankingnews.com

Healios K.K. (OTCMKTS:HLOSF) Stock Price Up 5.6%

See More Headlines

Receive HLOSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Healios K.K. and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:HLOSF
CUSIP: N/A
CIK: N/A
Web: healios.co.jp
Phone: 81357778308
Fax: N/A
Employees: 71
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Tadahisa S. Kagimoto M.D. (Age 48)
Chairman & CEO
Mr. Richard P. Kincaid (Age 48)
CFO, Executive Officer & Internal Director
Mr. Masanori Sawada M.D. (Age 43)
MBA, Ph.D., Executive VP, Chief Medical Officer and In Charge of Development & Human Resources & General Affairs
Mr. Kouichi Tamura Ph.D. (Age 68)
Exec. Off., Chief Scientific Off., In Charge of Res. & Manufacturing and Head of Kobe Res. Institute
Mr. Yoshinari Matsuda (Age 46)
Managing Director

Key Competitors

View All Competitors

HLOSF Stock Analysis - Frequently Asked Questions

How have HLOSF shares performed in 2024?: Healios K.K.'s stock was trading at 1.59 at the beginning of the year. Since then, HLOSF stock has decreased by 37.4% and is now trading at 0.99.
View the best growth stocks for 2024 here.
Are investors shorting Healios K.K.?: Healios K.K. saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 365,900 shares, a drop of 6.4% from the March 31st total of 391,100 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
View Healios K.K.'s Short Interest.
How do I buy shares of Healios K.K.?: Shares of HLOSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HLOSF) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial